Compare IDEXX Laboratories, Inc. (IDXX) vs Morgan Stanley (MS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Morgan Stanley — how do they compare? IDEXX Laboratories, Inc. trades at $572.2 (market cap $46.22B), while Morgan Stanley trades at $218.58 (market cap $338.09B). The key difference: Morgan Stanley is far larger — about 7.3× IDEXX Laboratories, Inc.'s market cap, and Morgan Stanley pays a 2.14% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | MS | |
|---|---|---|
Market Cap | $46.22B | $338.09B |
Sector | Health | Financials |
52-Week High | $766.68 | $228.42 |
52-Week Low | $526.44 | $144.04 |
Enterprise Value | $47.12B | — |
Dividend Yield | — | 2.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Morgan Stanley (MS) trades at $215.27, down 0.46% on the day, with a neutral technical signal. The stock shows strong fundamentals, with revenue growing from $50.2B in 2022 to $66.0B in 2025 and net income margin expanding to 27.59%. Recent earnings beats and the selection to lead the Anthropic IPO highlight operational strength. The consensus analyst price target is $239.58, implying potential upside.
The outlook is positive, supported by earnings momentum and strategic initiatives like AI integration in wealth management. Key risks include volatile cash flows from operations and high leverage, with debt-to-asset ratio rising to 26.1 in 2025. Analyst sentiment is bullish, with 55.77% recommending Buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
